Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06087965
Other study ID # 202307-11
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 11, 2023
Est. completion date December 30, 2025

Study information

Verified date October 2023
Source Tang-Du Hospital
Contact Zhihong Li
Phone +86-13709183909
Email 409615390@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intracerebral hemorrhage (ICH) is a critical disease of public health importance. Inflammatory mechanisms play a significant role in ICH. Thus, immune targets are supposed to be effective in protecting the neurological function of ICH. Fingolimod, a sphingosine-1-phosphate receptor regulator (FTY720), is an effective immunology modulator. It has been widely used in autoimmune disease and has also been testified effective in ICH who received conservative treatment. The present study aims to evaluate the efficiency and safety of fingolimod for ICH with minimal invasive treatment.


Description:

40 ICH patients who meet the inclusion criteria will be enrolled in the present study. All ICH patients will be screened. If meeting the including criteria, the investigators will contact the family, explain the study, and send a consent form for review. After obtaining written consent from the family, patients randomly assigned to the fingolimod group will be given 0.5mg/day oral fingolimod over a course of 3 consecutive days. Patients assigned to the control group will not receive fingolimod. All patients will receive minimal invasive puncture and drainage of hematoma. The investigators will evaluate the neurofunctional before and 30 days, 90 days and 180 days after oral fingolimod. CT scan will be performed at before, 7 and 14 days after oral fingolimod. 5ml intravenous blood for flow cytometry is also taken before and 1day, 3days, 7days after fingolimod use.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 30, 2025
Est. primary completion date June 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - spontaneous basal ganglia ICH with volume larger than 20ml; - age: 18-80 years; - admission Glasgow Coma Scale score: 5-12; - admitting to hospital with 24 hours after injury; - no fever or signs infection on admission to hospital; - admission heart rate=60/min on admission. Exclusion Criteria: - refuse follow-up; - received operation before admitting to hospital; - hemorrhage by tumor, arteriovenous malformation, arterial aneurysm, hematological disease or traumatic brain injury; - severe vomiting; - mRS>1 before ICH; - prior history of bradycardia; - prior history of Atrioventricular block; - prior history of traumatic brain injury, craniotomy or stroke; - expected lifetime less than 1 year; - undergoing antitumor, antiepileptic, immunomodulatory or immunosuppressive therapy; - admitting to other ongoing study; - systemic disease: uremia, liver cirrhosis, malignant tumor, mental disease, drug or alcohol dependence; - received anticoagulant or antiplatelet therapy within 7 days; - intraventricular hemorrhage requires intraventricular catheterization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fingolimod
0.5mg/day oral fingolimod over a course of 3 consecutive days

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tang-Du Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary modified Rankin Scale Neurological outcome, range: 0-6. The higher scores mean a worse outcome. 90 days and 180 days after ICH
Secondary The National Institutes of Health Stroke Scale Neurological outcome, range: 0-42. The higher scores mean a worse outcome. 90 days and 180 days after ICH
Secondary Modified Barthel Index Neurological outcome, range: 0-100. The higher scores mean a better outcome. 90 days and 180 days after ICH
Secondary Montreal Cognitive Assessment Scale Neurological outcome, range: 0-30. The higher scores mean a better outcome. 90 days and 180 days after ICH
Secondary Volume of perihematomal edema Volume of perihematomal edema measured on head Computerised Tomography Baseline on admission, 7 days and 14 days after ICH
See also
  Status Clinical Trial Phase
Recruiting NCT05089331 - ROSE-Longitudinal Assessment With Neuroimaging
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Active, not recruiting NCT04522102 - Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase Phase 3
Terminated NCT04178746 - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting NCT03956485 - Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Enrolling by invitation NCT02920645 - Multicenter Validation of the AVICH Score N/A
Recruiting NCT02625948 - Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign Phase 2
Completed NCT02478177 - Addressing Real-world Anticoagulant Management Issues in Stroke
Completed NCT01971359 - Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study N/A
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Terminated NCT00990509 - Albumin for Intracerebral Hemorrhage Intervention Phase 2
Completed NCT00716079 - The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial N/A
Recruiting NCT00222625 - rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets Phase 2
Recruiting NCT05095857 - The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury Phase 4
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Not yet recruiting NCT06429332 - International Care Bundle Evaluation in Cerebral Hemorrhage Research Phase 4
Recruiting NCT05492474 - Cranial Ultrasound for Prehospital ICH Diagnosis N/A
Not yet recruiting NCT05502874 - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting NCT04604587 - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA Phase 3
Recruiting NCT05504941 - Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage N/A